Trial Profile
A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mmexp3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ESPRIT
- 01 Jun 2012 Actual patient number changed from 4241 to 4169 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Actual patient number changed from 4241 to 4169 as reported by ClinicalTrials.gov.
- 01 Apr 2011 Results published in HIV Medicine.